Nonprescription Drugs:

Over the Counter and Underemphasized

PEMD-92-9: Published: Jan 10, 1992. Publicly Released: Feb 27, 1992.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

Pursuant to a congressional request, GAO reviewed the Food and Drug Administration's (FDA) procedures for approving and monitoring over-the-counter (OTC) drugs, focusing on: (1) procedural vulnerabilities that could result in the approval and marketing of unsafe and ineffective drugs; and (2) procedures for approving prescription drugs compared to OTC drug procedures.

GAO found that: (1) unlike prescription drugs, FDA does not require some OTC drugs to demonstrate their safety and effectiveness; (2) during FDA inspections for compliance with current good manufacturing practices, FDA has statutory authority to inspect prescription drug manufacturers' records and documents, but not OTC drug manufacturers' documents; (3) FDA collects less post-marketing surveillance information and conducts fewer product performance analyses for OTC drugs than for prescription drugs; and (4) post-marketing responses collected for prescription drugs include patterns of usage, the magnitude of any identified problems and the appropriate level of response, and trends in adverse reactions.

Sep 15, 2016

Sep 14, 2016

Sep 12, 2016

Sep 9, 2016

Sep 6, 2016

Aug 31, 2016

Looking for more? Browse all our products here